ATE236193T1 - Synthetische peptide spezifisch gegen anti- basisches-myelin-protein aus cerebrospinalflüssigkeit von individuen mit multipler sklerose - Google Patents

Synthetische peptide spezifisch gegen anti- basisches-myelin-protein aus cerebrospinalflüssigkeit von individuen mit multipler sklerose

Info

Publication number
ATE236193T1
ATE236193T1 AT93908754T AT93908754T ATE236193T1 AT E236193 T1 ATE236193 T1 AT E236193T1 AT 93908754 T AT93908754 T AT 93908754T AT 93908754 T AT93908754 T AT 93908754T AT E236193 T1 ATE236193 T1 AT E236193T1
Authority
AT
Austria
Prior art keywords
mbp
synthetic peptides
multiple sclerosis
residues
antibasic
Prior art date
Application number
AT93908754T
Other languages
English (en)
Inventor
Kenneth G Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of ATE236193T1 publication Critical patent/ATE236193T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93908754T 1991-10-22 1992-10-15 Synthetische peptide spezifisch gegen anti- basisches-myelin-protein aus cerebrospinalflüssigkeit von individuen mit multipler sklerose ATE236193T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002053799A CA2053799C (en) 1991-10-22 1991-10-22 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
PCT/CA1992/000448 WO1993008212A1 (en) 1991-10-22 1992-10-15 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid

Publications (1)

Publication Number Publication Date
ATE236193T1 true ATE236193T1 (de) 2003-04-15

Family

ID=4148603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93908754T ATE236193T1 (de) 1991-10-22 1992-10-15 Synthetische peptide spezifisch gegen anti- basisches-myelin-protein aus cerebrospinalflüssigkeit von individuen mit multipler sklerose

Country Status (12)

Country Link
EP (1) EP0610446B1 (de)
AT (1) ATE236193T1 (de)
AU (1) AU2750092A (de)
CA (1) CA2053799C (de)
DE (1) DE69232987T2 (de)
DK (1) DK0610446T3 (de)
ES (1) ES2196007T3 (de)
FI (1) FI111050B (de)
NO (1) NO310513B1 (de)
NZ (1) NZ244807A (de)
RU (1) RU2121850C1 (de)
WO (1) WO1993008212A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SI9520118A (sl) * 1994-10-25 1998-08-31 Immulogic Pharmaceutical Corporation Sestavki in zdravljenje multiple skleroze
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
DE69525544T2 (de) * 1994-11-18 2002-08-22 Neurocrine Biosciences Inc Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
WO2005009455A1 (fr) * 2003-07-29 2005-02-03 Terentiev Alexandr Alexandrovi Composition de peptides presentant une propriete immunoregulatrice
KR20120103591A (ko) 2009-10-12 2012-09-19 라이프바이오 라보라토리즈 엘엘씨 다발성 경화증 치료용 조성물
US9326773B2 (en) 2012-01-26 2016-05-03 Covidien Lp Surgical device including buttress material
WO2024094562A1 (en) * 2022-11-01 2024-05-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis

Also Published As

Publication number Publication date
NO941415L (de) 1994-06-22
ES2196007T3 (es) 2003-12-16
RU2121850C1 (ru) 1998-11-20
CA2053799C (en) 2002-03-12
DE69232987T2 (de) 2004-01-29
AU2750092A (en) 1993-05-21
EP0610446B1 (de) 2003-04-02
FI941860A (fi) 1994-04-21
FI941860A0 (fi) 1994-04-21
WO1993008212A1 (en) 1993-04-29
DK0610446T3 (da) 2003-07-14
CA2053799A1 (en) 1993-04-23
NO310513B1 (no) 2001-07-16
EP0610446A1 (de) 1994-08-17
RU94027578A (ru) 1996-10-20
FI111050B (fi) 2003-05-30
NZ244807A (en) 1997-08-22
DE69232987D1 (de) 2003-05-08
NO941415D0 (no) 1994-04-19

Similar Documents

Publication Publication Date Title
ATE236193T1 (de) Synthetische peptide spezifisch gegen anti- basisches-myelin-protein aus cerebrospinalflüssigkeit von individuen mit multipler sklerose
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
FI832095L (fi) Dynorfinamidanaloger
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
IL116559A0 (en) Chimeric proteins
ATE201415T1 (de) Spezifische peptid-wirksamkeit von anti-myelin basischem protein und die anwendung von myelin basischen protein-peptiden an multiple-sklerose- patienten
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
FI942392A0 (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
ATE400582T1 (de) Myelin basic protein peptidfragmente, deren pharmazeutische zusammensetzungen und verwendung gegen multiple sklerose
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0610446

Country of ref document: EP

REN Ceased due to non-payment of the annual fee